.  .
͡ .

䫵 KnowSteroid

Facebook ɳ

Facebook ´
Facebook Twitter
Youtube .


Ѻا : 7/03/2018
Online User Last 1 hour (0 users)

  Two Recent UNDP Publications
  01 Ҿѹ 2554

Date: 1 February 2011


The report entitled "Five years into the product patent regime: India`s response" is intended to be a contribution towards understanding the continued role of India as a supplier of affordable medicines five years after having complied with the TRIPS Agreement.  The report compiles three main studies commissioned by UNDP by: Sudip Chaudhuri, Chan Park and K. M. Gopakumar. The studies demonstrate that developments in India have impacts well beyond its borders, given the reliance thus far of much of the global market, especially in developing countries and LDCs, on the supply of low-cost, quality Indian generic pharmaceutical products. The studies analyze the role of both the Indian pharmaceutical industry and the Indian legal system in building a post-TRIPS scenario that continue to be conducive to sourcing affordable medicines.

The Good Practice Guide: Improving Access to Treatment by Utilizing Public Health Flexibilities in the WTO TRIPS Agreement has been prepared by the UNDP HIV/AIDS Group at the Bureau for Development Policy. In line with the objectives of the UNAIDS Strategy 2011 - 2015 "Getting to Zero", the Good Practice Guide explains the impact of and connection between intellectual property rights and access to treatment. The Guide analyses many of the public health flexibilities in the TRIPS Agreement and provides examples where and how have they been used by national governments. This Guide can be used by legislators, policy makers and government officials in discussions on adopting or reforming relevant legislation, in the process of formulating national IPR and public health policies, as well as in negotiating WTO accession agreements, or bilateral trade agreements that contain reference to IPR obligations. As a tool, this Good Practice Guide provides the basics.

Keywords: Patent / HIV/AIDS / India